Article · Wikipedia archive · Last revised Jun 6, 2026

SPL028

SPL028, or SPL-028, also known as α,α-dideutero-N,N-dimethyltryptamine (D2-DMT), is a psychedelic drug of the tryptamine family which is under development for the treatment of depressive disorders. It is the analogue of dimethyltryptamine (DMT) in which the α carbon has been dideuterated. SPL028's route of administration is intravenous injection or intramuscular injection.

Last revised
Jun 6, 2026
Read time
≈ 2 min
Length
535 w
Citations
19
Source
Wikipedia ↗
SPL028
Clinical data
Other namesSPL-028; α,α-Dideutero-N,N-dimethyltryptamine; N,N-D2-dimethyltryptamine; D2-DMT; DMT-d2
Routes of
administration		Intravenous injection, intramuscular injection1
Drug classSerotonin receptor modulator; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
PubChem CID
ChemSpider
Chemical and physical data
3D model (JSmol)
  • [2H]C([2H])(CC1=CNC2=CC=CC=C21)N(C)C
  • InChI=1S/C12H16N2/c1-14(2)8-7-10-9-13-12-6-4-3-5-11(10)12/h3-6,9,13H,7-8H2,1-2H3/i8D2
  • Key:DMULVCHRPCFFGV-MGVXTIMCSA-N

SPL028, or SPL-028, also known as α,α-dideutero-N,N-dimethyltryptamine (D2-DMT), is a psychedelic drug of the tryptamine family which is under development for the treatment of depressive disorders.2345 It is the analogue of dimethyltryptamine (DMT) in which the α carbon has been dideuterated.26 SPL028's route of administration is intravenous injection or intramuscular injection.1

Pharmacology

SPL028 shows similar pharmacodynamics as DMT in vitro.26 Relatedly, SPL028 generalized with DMT in rodent drug discrimination tests.67 On the other hand, SPL028 differs from DMT in terms of pharmacokinetics; it is more resistant to metabolism and shows a prolonged duration.267 In a phase 1 clinical trial, SPL-028 by intramuscular injection produced robust psychedelic effects of short duration in humans.8

Research

SPL028 was originated by Small Pharma and is under development by Cybin.4 Small Pharma was acquired by Cybin in 2023.9 As of February 2024, SPL028 is in phase 1 clinical trials.4

See also

See also

References

References

  1. Marino D (15 February 2023). "First Subject Dosed in Small Pharma's First-in-Human Phase 1 Clinical Trial". Drug Development and Delivery. Retrieved 27 July 2025.
  2. Layzell M, Rands P, Good M, Joel Z, Cousins R, Benway T, et al. (14 September 2023). "Discovery and In Vitro Characterization of SPL028: Deuterated N , N -Dimethyltryptamine". ACS Medicinal Chemistry Letters. 14 (9): 1216–1223. doi:10.1021/acsmedchemlett.3c00143. ISSN 1948-5875. PMC 10510671. PMID 37736183.
  3. Kargbo RB (8 September 2022). "Application of Deuterated N , N -Dimethyltryptamine in the Potential Treatment of Psychiatric and Neurological Disorders". ACS Medicinal Chemistry Letters. 13 (9): 1402–1404. doi:10.1021/acsmedchemlett.2c00354. ISSN 1948-5875. PMC 9465894. PMID 36105328.
  4. "SPL 028". AdisInsight. 16 February 2024. Retrieved 27 July 2025.
  5. "Delving into the Latest Updates on SPL-028 with Synapse". Synapse. 14 June 2025. Retrieved 27 July 2025.
  6. Good M, Cheetham S, Davis I (2023). "The International BNA 2023 Festival of Neuroscience: Preclinical characterisation of SPL028: a deuterated derivative of N,N-dimethyltryptamine, developing a treatment for mental health disorders". Brain and Neuroscience Advances. 7: 77. doi:10.1177/23982128231180246. ISSN 2398-2128. PMC 10236260. The PK and pharmacology of SPL028 (α,α-bisdeutero-N,N-dimethyltryptamine (D2DMT) fumarate) [di-deuterated analogue of SPL026] was investigated through a series of preclinical studies. [...] SPL028 exhibited prolonged PK and pharmacodynamic effects compared to SPL026. In vitro & in vivo studies found the metabolic stability of SPL028 increased relative to SPL026. The in vitro & ex vivo receptor profiles of SPL028 and SPL026 were equivalent. These findings were consistent with drug discrimination study: rats were not able to distinguish SPL028 from SPL026.
  7. Good M, Joel Z, Cheetham S, Davis I, Rowley H, James E, et al. (April 2023). In vivo characterisation of SPL028: a deuterated derivative of N,N-dimethyltryptamine, developing a treatment for mental health disorders (PDF). British Neuroscience Association 2023 (BAN2023).
  8. "Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028". Nasdaq. 5 April 2024. Retrieved 27 July 2025.
  9. Alpha P (28 August 2023). "Cybin Set to Acquire British DMT Drug Developer Small Pharma". Psychedelic Alpha. Retrieved 27 July 2025.
External links